The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784 · cited 1×
“BRCA2 carriers may consider annual screening for pancreatic cancer with endoscopic ultrasound (EUS) or MRI/magnetic resonance cholangiopancreatography (MRCP) while being informed that data supporting this approach are very limited [V, C] [48].”
BackgroundEfficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743
Heemskerk-Gerritsen, B. A. M., Brekelmans, C. T. M., Menke-Pluymers, M. B. E., van Geel, A. N., Tilanus-Linthorst, M. M. A., Bartels, C. C. M., Tan, M., Meijers-Heijboer, H. E. J., Klijn, J. G. M., & Seynaeve, C. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9449-x · Cited by 153
Research works printed but not linked: 44
- Paul, 2014, The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers, Front Biosci (Landmark Ed), 19, 605, 10.2741/4230 · DOI · Paper page
- King, 2003, Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, 302, 643, 10.1126/science.1088759 · DOI · Paper page
- Walsh, 2011, Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing, Proc Natl Acad Sci USA, 108, 18032, 10.1073/pnas.1115052108 · DOI · Paper page
- Mersch, 2015, Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian, Cancer, 121, 2474, 10.1002/cncr.29041 · DOI · Paper page
- Ford, 1998, Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium, Am J Hum Genet, 62, 676, 10.1086/301749 · DOI · Paper page
- Roa, 1996, Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2, Nat Genet, 14, 185, 10.1038/ng1096-185 · DOI · Paper page
- Gabai-Kapara, 2014, Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2, Proc Natl Acad Sci USA, 111, 14205, 10.1073/pnas.1415979111 · DOI · Paper page
- Evans, 2010, Risk of breast cancer in male BRCA2 carriers, J Med Genet, 47, 710, 10.1136/jmg.2009.075176 · doi:10.1136/jmg.2009.075176
- Tai, 2007, Breast cancer risk among male BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst, 99, 1811, 10.1093/jnci/djm203 · DOI · Paper page
- Warner, 2004, Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination, JAMA, 292, 1317, 10.1001/jama.292.11.1317 · DOI · Paper page
- Kriege, 2004, Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition, N Engl J Med, 351, 427, 10.1056/NEJMoa031759 · DOI · Paper page
- Kuhl, 2005, Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer, J Clin Oncol, 23, 8469, 10.1200/JCO.2004.00.4960 · DOI · Paper page
- Chiarelli, 2014, Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the Ontario high risk breast screening program, J Clin Oncol, 32, 2224, 10.1200/JCO.2013.52.8331 · DOI
- Pijpe, 2012, Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK), BMJ, 345, e5660, 10.1136/bmj.e5660 · DOI · Paper page
- Phillips, 2013, Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 31, 3091, 10.1200/JCO.2012.47.8313 · DOI · Paper page
- Narod, 2000, Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group, Lancet, 356, 1876, 10.1016/S0140-6736(00)03258-X · DOI · Paper page
- Hartmann, 1999, Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, N Engl J Med, 340, 77, 10.1056/NEJM199901143400201 · DOI · Paper page
- Domchek, 2010, Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, JAMA, 304, 967, 10.1001/jama.2010.1237 · DOI · Paper page
- Evans, 2009, Risk reducing mastectomy: outcomes in 10 European centres, J Med Genet, 46, 254, 10.1136/jmg.2008.062232 · DOI
- Skytte, 2011, Breast cancer after bilateral risk-reducing mastectomy, Clin Genet, 79, 431, 10.1111/j.1399-0004.2010.01604.x · DOI
- Mulligan, 2011, Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2, Breast Cancer Res, 13, R110, 10.1186/bcr3052 · DOI
- Morrow, 2009, Prophylactic mastectomy and the timing of breast reconstruction, Br J Surg, 96, 1, 10.1002/bjs.6463 · doi:10.1002/bjs.6463
- Niemeyer, 2011, Extended indications for nipple-sparing mastectomy, Breast J, 17, 296, 10.1111/j.1524-4741.2011.01079.x · doi:10.1111/j.1524-4741.2011.01079.x
- Chung, 2008, Nipple-sparing mastectomy: where are we now?, Surg Oncol, 17, 261, 10.1016/j.suronc.2008.03.004 · doi:10.1016/j.suronc.2008.03.004
- Kiely, 2010, Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Breast Cancer Res Treat, 120, 715, 10.1007/s10549-009-0497-8 · DOI
- Metcalfe, 2014, Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis, BMJ, 348, g226, 10.1136/bmj.g226 · DOI · Paper page
- Heemskerk-Gerritsen, 2015, Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis, Int J Cancer, 136, 668, 10.1002/ijc.29032 · DOI · Paper page
- Rebbeck, 1999, Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers, J Natl Cancer Inst, 91, 1475, 10.1093/jnci/91.17.1475 · DOI · Paper page
- Rebbeck, 2009, Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers, J Natl Cancer Inst, 101, 80, 10.1093/jnci/djn442 · DOI · Paper page
- Heemskerk-Gerritsen, 2015, Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction, J Natl Cancer Inst, 107, djv033, 10.1093/jnci/djv033 · DOI · Paper page
- Friebel, 2014, Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis, J Natl Cancer Inst, 106, dju091, 10.1093/jnci/dju091 · DOI · Paper page
- Menon, 2015, Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening, J Clin Oncol, 33, 2062, 10.1200/JCO.2014.59.4945 · DOI · Paper page
- Greene, 2008, A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study, Cancer Epidemiol Biomarkers Prev, 17, 594, 10.1158/1055-9965.EPI-07-2703 · DOI
- Finch, 2014, Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation, J Clin Oncol, 32, 1547, 10.1200/JCO.2013.53.2820 · DOI · Paper page
- Marchetti, 2014, Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers, BMC Womens Health, 14, 150, 10.1186/s12905-014-0150-5 · DOI · Paper page
- Swanson, 2016, Options in prophylactic surgery to prevent ovarian cancer in high-risk women: how new hypotheses of fallopian tube origin influence recommendations, Curr Treat Options Oncol, 17, 20, 10.1007/s11864-016-0396-2 · DOI
- Shapira, 2015, BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles, Fert Steril, 104, 1162, 10.1016/j.fertnstert.2015.07.1162 · doi:10.1016/j.fertnstert.2015.07.1162
- Peccatori, 2013, Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 24, vi160, 10.1093/annonc/mdt199 · DOI · Paper page
- Rebbeck, 2005, Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol, 23, 7804, 10.1200/JCO.2004.00.8151 · DOI · Paper page
- Santen, 2015, Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels, Climacteric, 18, 121, 10.3109/13697137.2014.947254 · DOI · Paper page
- Coleman, 2014, Bone health in cancer patients: ESMO Clinical Practice Guidelines, Ann Oncol, 25, iii124, 10.1093/annonc/mdu103 · DOI · Paper page
- Easton, 2015, Gene-panel sequencing and the prediction of breast-cancer risk, N Engl J Med, 372, 2243, 10.1056/NEJMsr1501341 · DOI · Paper page
- Rebbeck, 2015, Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer, JAMA, 313, 1347, 10.1001/jama.2014.5985 · DOI · Paper page
- Dykewicz, 2001, Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, Clin Infect Dis, 33, 139, 10.1086/321805 · DOI · Paper page
Cited by
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Self-citationEarly breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Self-citation3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
Self-citationMultiple primary tumours: challenges and approaches, a review
Vogt, A., Schmid, S., Heinimann, K., Frick, H., Herrmann, C., Cerny, T., & Omlin, A. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000172 · Cited by 628
Metadata
- Authors
- Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 27
- Issue
- suppl 5
- Pages
- v103-v110
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2527255307
- Cited by
- 399
- References
- 5
- FWCI
- 23.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1209 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. https://app.cochat.ai/papers/10.1093/annonc/mdw327
- The paper
- Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E. (2016). Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Annals of Oncology. https://doi.org/10.1093/annonc/mdw327
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.